We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+3.9%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$270M
AUM Growth
-$974K
Cap. Flow
+$3.47M
Cap. Flow %
1.29%
Top 10 Hldgs %
48.55%
Holding
70
New
8
Increased
19
Reduced
15
Closed
6

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$7.67M
2
AMGN icon
Amgen
AMGN
+$7.52M
3
INSM icon
Insmed
INSM
+$6.87M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.93M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$4.37M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$8.83M
2
AERI
Aerie Pharmaceuticals
AERI
+$7.18M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$5.83M
4
WVE icon
Wave Life Sciences
WVE
+$5.63M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$5.52M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
26
Amarin Corp
AMRN
$297M
$2.65M 0.98%
6,850
– –
ARQL
27
DELISTED
Arqule Inc
ARQL
$2.63M 0.98%
+239,103
New +$1.66M
IOVA icon
28
Iovance Biotherapeutics
IOVA
$3.74B
$2.54M 0.94%
+104,000
New +$1.57M
ALNY icon
29
Alnylam Pharmaceuticals
ALNY
$31.7B
$2.45M 0.91%
33,800
– –
BHVN
30
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.23M 0.83%
50,949
+20,949
+70% +$1.18M
XENT
31
DELISTED
Intersect ENT, Inc
XENT
$2.18M 0.81%
96,000
– –
BLUE
32
DELISTED
bluebird bio
BLUE
$2.16M 0.8%
1,312
– –
QURE icon
33
uniQure
QURE
$3.44B
$2.15M 0.8%
+27,500
New +$1.75M
NKTR icon
34
Nektar Therapeutics
NKTR
$2.55B
$2.13M 0.79%
4,000
– –
RGEN icon
35
Repligen
RGEN
$10.3B
$2.06M 0.76%
+24,000
New +$1.64M
TPST icon
36
Tempest Therapeutics
TPST
$17.9M
$2.06M 0.76%
912
+595
+188% +$1.75M
GWPH
37
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.9M 0.7%
11,000
-5,800
-35% -$1M
AGIO icon
38
Agios Pharmaceuticals
AGIO
$2.05B
$1.82M 0.68%
36,500
– –
STRO icon
39
Sutro Biopharma
STRO
$353M
$1.64M 0.61%
14,515
-150
-1% -$16.5K
SGMO
40
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.62M 0.6%
150,000
+102,000
+213% +$1.08M
BPMC
41
DELISTED
Blueprint Medicines
BPMC
$1.6M 0.59%
+17,000
New +$1.4M
ALKS icon
42
Alkermes
ALKS
$8.2B
$1.58M 0.59%
70,000
-163,000
-70% -$4.47M
MYOK
43
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.5M 0.56%
30,000
– –
GBT
44
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.47M 0.55%
28,000
– –
ACAD icon
45
Acadia Pharmaceuticals
ACAD
$5.12B
$1.42M 0.52%
53,000
-216,000
-80% -$5.52M
EXAS
46
DELISTED
Exact Sciences
EXAS
$1.26M 0.47%
+10,700
New +$1.08M
XLRN
47
DELISTED
Acceleron Pharma
XLRN
$1.23M 0.46%
30,000
– –
MRTX
48
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.12M 0.42%
10,900
-10,800
-50% -$841K
MYGN icon
49
Myriad Genetics
MYGN
$304M
$1.11M 0.41%
40,000
+1,635
+4% +$46.2K
GMED icon
50
Globus Medical
GMED
$11.1B
$1.02M 0.38%
24,200
– –
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2019 Portfolio in Review

As of Q2 2019, International Biotechnology Trust held 70 positions worth $270M, down 0.36% from $271M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

International Biotechnology Trust's Q2 2019 filing shows 8 new, 19 increased, 15 reduced and 6 closed positions. Its largest new stake was uniQure: 27,500 shares worth $2.15M. The largest sale was Celgene Corp, an estimated $8.83M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q2 2019 buy was uniQure: 27,500 shares worth $2.15M.
  • International Biotechnology Trust added most to Biogen in Q2 2019, an estimated $7.67M increase.
  • International Biotechnology Trust's biggest Q2 2019 reduction was Celgene Corp, cutting an estimated $8.83M.
  • International Biotechnology Trust fully exited Aerie Pharmaceuticals in Q2 2019, selling an estimated $7.18M.
  • International Biotechnology Trust's ten largest holdings make up 49% of its $270M portfolio in Q2 2019.
  • International Biotechnology Trust opened 8 new positions and closed 6 in Q2 2019.
  • International Biotechnology Trust's portfolio value fell 0.36% quarter-over-quarter to $270M.

Based on International Biotechnology Trust's 13F filing for Q2 2019, filed 14 Aug 2019.